CDH5 and persistent truncus arteriosus: Compared with the Sham control, there was a 2.69-fold decrease in the number of CD31+/VE-Cadherin+ endothelial cells, and about a 2.85-fold increase in the number of CD31+/α-SMA+ (α-smooth muscle actin, myofibroblast marker) cells in the TAC group.